(R)-tert-butyl 3-(6-chloro-2-morpholinopyrimidin-4-yloxy)pyrrolidine-1-carboxylate | 944402-21-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-tert-butyl 3-(6-chloro-2-morpholinopyrimidin-4-yloxy)pyrrolidine-1-carboxylate
• 英文别名: tert-butyl (3R)-3-(6-chloro-2-morpholin-4-ylpyrimidin-4-yl)oxypyrrolidine-1-carboxylate
• CAS: 944402-21-5
• 化学式: C₁₇H₂₅ClN₄O₄
• 分子量: 384.863
• InChiKey: WVYZDRRGQXGCSC-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  77
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS
  申请人：Burger Matthew

  公开号：US20100249126A1

  公开（公告）日：2010-09-30

  Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

  磷脂鞘氨醇（PI）3-激酶抑制剂化合物（I），其药学上可接受的盐和前药；新化合物的组合物，可单独使用或与至少一种额外治疗剂联合使用，与药学上可接受的载体；以及新化合物的用途，可单独使用或与至少一种额外治疗剂联合使用，用于预防或治疗通过生长因子、蛋白质丝氨酸/苏氨酸激酶和磷脂酰肌醇激酶异常活性所表现的增殖性疾病。
• PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS
  申请人：BURGER Matthew

  公开号：US20120225859A1

  公开（公告）日：2012-09-06

  Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

  磷脂酰肌醇（PI）3-激酶抑制剂化合物（I），其药学上可接受的盐和前药；新化合物的组合物，可以单独使用或与至少一种额外治疗剂联合使用，以药学上可接受的载体为基础；新化合物的用途，可以单独使用或与至少一种额外治疗剂联合使用，用于预防或治疗增殖性疾病，其特征是生长因子，蛋白丝氨酸/苏氨酸激酶和磷脂酰肌醇激酶的异常活性。
• Pyrimidine derivatives used as pi-3 kinase inhibitors
  申请人：Novartis AG

  公开号：EP2261223A1

  公开（公告）日：2010-12-15

  Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

  磷脂酰肌醇 (PI) 3- 激酶抑制剂化合物 (I)、其药学上可接受的盐类，与至少一种额外的治疗剂和药学上可接受的载体结合使用；用于预防或治疗以生长因子、蛋白丝氨酸/苏氨酸激酶和磷脂激酶活性异常为特征的增殖性疾病。
• US8217035B2
  申请人：——

  公开号：US8217035B2

  公开（公告）日：2012-07-10
• US8563549B2
  申请人：——

  公开号：US8563549B2

  公开（公告）日：2013-10-22